U.S. FDA Grants Interchangeability Designation to Samsung Bioepis and Organon’s Humira Biosimilar
The U.S. Food and Drug Administration (FDA) has designated the Hadlima (adalimumab-bwwd) high- and low-concentration (40mg/0.4mL, 40mg/0.8mL) autoinjectors and high-concentration prefilled syringe as interchangeable biosimilars to Humira (adalimumab).